PT-141 Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is PT-141?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Generic Name: Bremelanotide
• Research Name: PT-141
• Brand Name (FDA-Approved): Vyleesi
• Primary Research Areas: Sexual desire disorders, erectile dysfunction, female sexual arousal disorder, melanocortin system biology
• Compound Class: Synthetic cyclic heptapeptide; melanocortin receptor agonist
• Molecular Weight: 1,025.2 g/mol
• Key Mechanisms: MC3R and MC4R agonism, dopamine pathway activation, nitric oxide release via CNS signaling
• Published Studies: Multiple Phase I, II, and III clinical trials completed; FDA NDA 210557 approved
• Clinical Trial Status: FDA-approved for HSDD in premenopausal women; ongoing research in male ED and treatment-resistant populations
• Regulatory Classification: FDA-approved pharmaceutical (Vyleesi); research peptide classification applies to non-approved uses and investigational doses
• Notable Distinction: Acts centrally through brain melanocortin receptors, not peripherally through vascular mechanisms

What is PT-141?

PT-141, known generically as bremelanotide, is a synthetic cyclic heptapeptide developed as a structural analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH is a naturally occurring peptide hormone produced in the pituitary gland that regulates diverse physiological processes including pigmentation, energy balance, inflammation, and sexual behavior. PT-141 was engineered to preserve the receptor-binding properties of alpha-MSH while enhancing stability and selectivity for the melanocortin receptor subtypes most relevant to sexual function.

The compound emerged from research into melanotan peptides, a family of alpha-MSH analogs originally investigated for their skin-tanning properties. During early clinical investigations with a related compound, melanotan II, researchers observed unexpected spontaneous erections in male subjects. This finding redirected research toward the sexual function applications of melanocortin receptor activation. PT-141 was subsequently developed as a purpose-designed compound for investigating these effects, with greater receptor selectivity and a more favorable safety profile than its predecessors.

What makes PT-141 scientifically distinctive is its site of action. Rather than working on blood vessels or other peripheral tissues, PT-141 activates receptors located primarily in the hypothalamus and other brain regions involved in sexual behavior. This central mechanism means it can influence sexual desire and arousal through neurochemical pathways, a fundamentally different approach than vasodilatory agents that work by increasing genital blood flow. The compound has demonstrated effects in both male and female subjects across multiple clinical trials, and it achieved FDA approval in 2019 under the brand name Vyleesi for a specific indication in women.

Research into PT-141 represents one of the few examples of a research peptide completing the full clinical development pathway to regulatory approval, providing a robust body of clinical data that distinguishes it from most compounds in this research category.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

PT-141 adopts a cyclic conformation that distinguishes it from linear peptide analogs. The cyclic structure creates a constrained three-dimensional shape that fits melanocortin receptor binding pockets with high affinity, particularly MC4R. This conformational constraint also provides resistance to enzymatic degradation, extending its biological activity compared to linear alpha-MSH.

The peptide contains the His-Phe-Arg-Trp core sequence present in alpha-MSH, which represents the minimal pharmacophore required for melanocortin receptor binding. Modifications to the flanking residues and the cyclic backbone distinguish PT-141 from alpha-MSH and from related analogs, giving it a receptor binding profile biased toward MC3R and MC4R over MC1R and MC2R. MC1R mediates skin pigmentation, and selective avoidance of this receptor reduces the pigmentation-related effects observed with earlier analogs.

The cyclic architecture also contributes to PT-141’s sustained receptor engagement. Despite a plasma half-life of approximately two hours, its biological effects on sexual function persist for four to eight hours in clinical observations, a duration that exceeds what the pharmacokinetic profile alone would predict and that likely reflects receptor residence time and downstream neurochemical changes following initial activation.

Mechanisms of Action Being Investigated

PT-141 activates melanocortin receptors in the central nervous system, triggering a cascade of neurochemical events that modulate sexual desire and arousal. The compound’s mechanism differs fundamentally from peripherally acting agents and spans multiple neurotransmitter systems.

MC3R and MC4R Receptor Agonism

PT-141 binds with high affinity to both MC3R and MC4R, with preferential activity at MC4R. These receptors are expressed predominantly in hypothalamic nuclei, particularly the paraventricular nucleus (PVN), which serves as a key integration center for sexual behavior, appetite, and autonomic function.

MC4R activation is the primary driver of PT-141’s sexual function effects. Studies using MC4R knockout animal models show abolished erectogenic responses to melanocortin agonists, confirming the receptor’s essential role. MC3R activation contributes to the overall pharmacological profile but plays a secondary role relative to MC4R in sexual function pathways [1].

Intracellular Signaling: cAMP Pathway Activation

Receptor binding couples to adenylyl cyclase through stimulatory G proteins. Adenylyl cyclase activation increases intracellular cyclic adenosine monophosphate (cAMP) production within hypothalamic neurons. Elevated cAMP enhances neuronal excitability in the regions governing sexual behavior, creating the downstream effects observed in preclinical and clinical research [2].

Increased c-Fos immunoreactivity in hypothalamic regions following PT-141 administration in rat and primate models provides direct evidence of this neuronal activation. Pseudorabies virus tracing studies have further confirmed anatomical connections between hypothalamic MC4R sites and penile innervation pathways, establishing the neural circuit linking central receptor activation to peripheral sexual response [3].

Dopamine and Reward Circuit Modulation

MC4R activation in the mesolimbic system increases dopamine activity in reward-processing circuits. Dopamine release in these pathways generates the motivational and desire components of sexual arousal, distinct from the physical arousal response. This mechanism explains why PT-141 can increase sexual interest and motivation rather than simply facilitating physical response, a capacity not shared by peripheral vascular agents [4].

The dopaminergic mechanism also provides a theoretical basis for PT-141’s activity in subjects with psychogenic components to sexual dysfunction. Animal studies show that melanocortin agonists increase proceptive sexual behaviors, a behavioral category reflecting active desire and motivation rather than passive response.

Norepinephrine and Arousal Enhancement

PT-141 enhances norepinephrine release in arousal-regulating brain regions. Norepinephrine contributes to heightened attentional focus and physiological arousal, complementing the motivational effects mediated through dopamine pathways. Together, these two catecholamine systems produce the combined desire and arousal effects documented in clinical trials [2].

Oxytocin Release from Hypothalamic Neurons

MC4R-expressing neurons in the paraventricular nucleus project to posterior pituitary regions where oxytocin is synthesized and released. PT-141 activation of these neurons promotes oxytocin release. Oxytocin contributes to social bonding, genital sensitivity, and the subjective experience of sexual arousal, adding a prosocial and sensory dimension to the compound’s sexual function effects [5].

Nitric Oxide Release via Central Activation

Central MC4R activation triggers nitric oxide (NO) release in neural pathways that innervate genital smooth muscle. This nitric oxide mediates smooth muscle relaxation in erectile tissue and genital vasculature, producing physical arousal responses. Critically, this NO release originates from a central neurological signal rather than from local vascular mechanisms, distinguishing it mechanistically from PDE5 inhibitors that act directly on penile vasculature [3].

Mechanistic Comparison with PDE5 Inhibitors

Major Areas of Research

PT-141 research spans multiple clinical populations and investigational contexts, with the largest body of evidence concentrated in two areas: female hypoactive sexual desire disorder and male erectile dysfunction.

Female Sexual Desire and Arousal Disorders

Female sexual dysfunction research represents the most extensively studied application of PT-141 and the pathway through which it achieved FDA approval. Hypoactive sexual desire disorder (HSDD) affects a substantial proportion of premenopausal women and is characterized by persistent absence of sexual desire causing personal distress, without a more explanatory psychiatric or medical condition.

The RECONNECT Phase 3 clinical program enrolled 1,247 premenopausal women with HSDD across two randomized, double-blind, placebo-controlled trials running 24 weeks each. Both trials met their co-primary endpoints: statistically significant improvements in satisfying sexual events (SSEs) and statistically significant reductions in distress associated with low sexual desire compared to placebo. A 52-week long-term extension study confirmed sustained effectiveness beyond the primary trial period [6].

Earlier Phase 2 work (NCT01382719, designated PT-141-54) provided the efficacy and safety signals that supported proceeding to Phase 3. This trial enrolled premenopausal women with female sexual arousal disorder (FSAD) and HSDD using subcutaneous bremelanotide, measuring change in satisfying sexual events as the primary endpoint alongside patient-reported desire assessments.

Key Research Highlights:

• Statistically significant improvement in satisfying sexual events versus placebo across both RECONNECT trials
• Significant reduction in distress related to low sexual desire
• 52-week data confirms sustained benefit without major long-term concerns
• Blood pressure increases noted and incorporated into safety labeling

Male Erectile Dysfunction Research

Male erectile dysfunction (ED) research with PT-141 has progressed through Phase I and Phase IIB trials, though it has not reached FDA approval for this indication. Early Phase I work established dose-dependent erectogenic effects through intranasal and subcutaneous routes in healthy males and ED patients, with responses measured by RigiScan penile tumescence monitoring [7].

A particularly important subpopulation studied was men with inadequate responses to sildenafil (Viagra). Subcutaneous PT-141 at doses of 4-6 mg produced significant erectile responses in this treatment-resistant group, establishing a potential role for melanocortin agonism in patients who fail standard PDE5 inhibitor therapy. A combination trial pairing low-dose intranasal PT-141 (7.5 mg) with low-dose sildenafil (25 mg) showed enhanced erectile response beyond sildenafil alone without increased adverse events, suggesting complementary mechanisms may allow lower doses of each agent when used together [8].

A 2024 open-label trial sponsored by Palatin Technologies enrolled 50 PDE5 inhibitor non-responders to investigate PT-141 combined with standard PDE5 inhibitor therapy, targeting topline results by end of 2024. This trial addresses a market gap estimated at approximately 40% of ED patients who fail standard first-line therapy [9].

Key Research Highlights:

• Dose-dependent erectogenic effects confirmed across intranasal and subcutaneous routes
• Efficacy demonstrated in men with inadequate responses to sildenafil
• Combination with low-dose sildenafil enhances response without increasing adverse events
• Ongoing trials targeting PDE5 inhibitor treatment-resistant populations

Melanocortin System Biology and Neuroscience

Beyond sexual function, PT-141 serves as a research tool for investigating melanocortin receptor biology in the CNS. The MC4R receptor participates in energy homeostasis, feeding behavior, inflammation, and autonomic regulation. PT-141’s selectivity for MC3R and MC4R over other melanocortin receptor subtypes makes it useful for dissecting these pathways in preclinical research [1].

Neuroprotective effects via MC4R activation represent an area of theoretical interest supported by preclinical signals. MC4R activation modulates neuroinflammatory responses and has shown protective effects in some brain injury models. Anti-inflammatory effects beyond the sexual function context are also theorized through melanocortin receptor pathways, though neither application has been confirmed in human clinical trials [10].

PT-141 has been described as a potential probe for studying melanocortin "regulatory amplifiers" in systems biology contexts, providing researchers with a pharmacological tool to examine how melanocortin signaling integrates with broader neuroendocrine networks.

Key Research Highlights:

• Preclinical signals for neuroprotective effects via MC4R
• Theoretical anti-inflammatory applications requiring further investigation
• Role as a pharmacological research tool for melanocortin system studies
• Potential integration with energy homeostasis and neuroendocrine research

Special Population Research: Diabetes and Spinal Cord Injury

Preclinical models have examined PT-141 in populations where standard erectile dysfunction treatments show reduced efficacy. Diabetic animal models and spinal cord injury models both showed efficacy signals for PT-141, providing a rationale for human clinical investigation in these populations. Both conditions impair peripheral vascular and neural pathways that PDE5 inhibitors rely upon, while PT-141’s central mechanism may be less affected by these peripheral deficits [4].

These applications remain at the preclinical or early investigational stage. No completed Phase II trials in diabetic patients or spinal cord injury populations have been published in the peer-reviewed literature as of the current research date.

Key Research Highlights:

• Efficacy signals in diabetic animal models where peripheral vascular dysfunction limits PDE5i response
• Preclinical signals in spinal cord injury models
• Central mechanism hypothesis suggests potential utility where peripheral pathways are impaired

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

PT-141 has been studied through two primary administration routes: subcutaneous injection and intranasal delivery. The FDA-approved formulation uses subcutaneous injection at 1.75 mg, which achieves reliable systemic absorption with a time to peak plasma concentration (Tmax) of approximately 30 minutes. The intranasal route studied in Phase I and II trials achieves similar Tmax values but requires substantially higher doses to produce equivalent plasma concentrations, reflecting lower bioavailability through the nasal mucosa compared to direct subcutaneous injection.

Dose-proportional pharmacokinetics have been confirmed across the studied dose ranges for both routes. Cmax and area under the curve (AUC) increase proportionally with dose, indicating linear pharmacokinetics without saturation effects at clinically relevant doses [7].

Distribution and Metabolism

PT-141 distributes rapidly into CNS tissue following systemic absorption, consistent with its pharmacodynamic profile. CNS penetration is rapid for both subcutaneous and intranasal routes, with neurological effects observable within 15-30 minutes of administration in most subjects. The cyclic peptide structure provides moderate resistance to peptidase degradation compared to linear peptide analogs, contributing to its pharmacological activity.

Plasma protein binding and volume of distribution data for PT-141 follow patterns typical for cyclic peptides of its molecular weight. Metabolism occurs through standard peptide degradation pathways with hydrolysis of peptide bonds by circulating and tissue-based peptidases.

Pharmacokinetic Parameters

Delivery Methods Under Investigation

• Subcutaneous injection: The FDA-approved route for Vyleesi; reliable absorption, consistent pharmacokinetics, used in Phase 3 RECONNECT trials at 1.75 mg
• Intranasal administration: Studied extensively in Phase I and Phase II male ED trials at doses of 7-20 mg; rapid CNS delivery with higher dose requirements due to variable mucosal absorption; associated with more adverse events than subcutaneous route in comparative studies

Excretion and Clearance

Clearance follows standard peptide elimination pathways. Plasma half-life of approximately 2 hours results in essentially complete systemic clearance within 8-10 hours of administration. The extended pharmacodynamic effect (4-8 hours) relative to plasma half-life suggests that downstream neurochemical changes, particularly in dopaminergic and oxytocinergic systems, persist beyond the period of active receptor occupancy. Renal and hepatic elimination pathways have not been fully characterized in published literature, and dose adjustment guidance in renal or hepatic impairment is not established outside of the FDA-approved indication.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data Scope While PT-141 has completed Phase 3 trials and achieved FDA approval for one indication (HSDD in premenopausal women), significant gaps remain in the clinical evidence base. The FDA approval covers only premenopausal women, leaving postmenopausal women, men, and all other potential populations without approved indications. Male ED data exists through Phase IIB but has not been taken through Phase 3. Long-term effects beyond 52 weeks are unstudied in any population [6].

Special Population Data Preclinical signals in diabetic and spinal cord injury models have not been followed by completed Phase 2 trials in human subjects. The theoretical benefits of a central mechanism in populations with peripheral vascular impairment remain unconfirmed in controlled human research. Pediatric and geriatric population data are absent, and postmenopausal women represent an unstudied population despite the prevalence of sexual desire disorders in this group [4].

Mechanistic Understanding The relative contributions of MC3R versus MC4R to PT-141’s clinical effects have not been fully dissected in human subjects. Preclinical knockout model data supports MC4R primacy, but receptor-selective pharmacology in the human CNS context remains incompletely characterized. The precise contribution of oxytocin release to clinical outcomes, and how this interacts with the dopaminergic and noradrenergic effects, requires further investigation [5].

Combination Therapy Research The combination of PT-141 with PDE5 inhibitors shows pharmacological rationale and early clinical signals, but definitive Phase 3 combination data does not exist. The 2024 open-label trial in 50 patients provides preliminary combination data but lacks the controlled design and sample size to support regulatory conclusions. The optimal dosing strategy for combination use remains undefined [8,9].

Areas Needing Further Investigation

• Male ED Phase 3 trials: the critical regulatory gap for expanding approved indications
• Postmenopausal female populations: unaddressed despite clinical relevance
• Long-term safety beyond 52 weeks: unknown for all populations
• Cardiovascular effects in at-risk populations: blood pressure effects noted in trials require characterization in patients with hypertension or cardiovascular disease
• Drug interaction profiles: incompletely characterized for common co-medications
• Diabetes and spinal cord injury populations: human trials needed to test preclinical signals

Regulatory and Research Status

Current Classification

FDA Status PT-141 (bremelanotide) received FDA approval on June 21, 2019, under the brand name Vyleesi. FDA NDA reference 210557 covers one specific indication: hypoactive sexual desire disorder (HSDD) in premenopausal women. The approved formulation is a 1.75 mg subcutaneous autoinjector used on an as-needed basis approximately 45 minutes before anticipated sexual activity.

The FDA approval does not extend to postmenopausal women, men, or any other indication. Use outside the approved indication, including investigational doses and routes studied in clinical trials, falls outside the approved label. For research purposes in non-approved populations or with non-approved formulations, PT-141 is subject to standard investigational new drug regulations [6].

WADA Status The World Anti-Doping Agency (WADA) prohibits bremelanotide in competitive athletics under the prohibited list category covering peptide hormones, growth factors, related substances, and mimetics. Athletes subject to anti-doping regulations must not use PT-141 or bremelanotide regardless of the administration method or clinical justification. This prohibition applies both in-competition and out-of-competition.

International Perspective PT-141 is approved only in the United States under the Vyleesi brand name for the HSDD indication. The European Medicines Agency (EMA) has not granted approval. In jurisdictions without FDA approval, the compound is classified as a research chemical subject to local regulatory frameworks. Regulatory status for the non-approved investigational applications studied in clinical trials varies by country.

Research Community Approach

PT-141’s unusual status as both an FDA-approved pharmaceutical and an active investigational compound creates a bifurcated research environment. For the approved indication, the compound is dispensed through standard pharmaceutical channels with full prescribing information and safety monitoring requirements. Investigational research in non-approved populations requires institutional review board oversight, appropriate informed consent procedures, and Investigational New Drug (IND) authorization from the FDA for studies conducted in the United States.

Palatin Technologies maintains the primary commercial and research interest in PT-141/bremelanotide, including the ongoing combination therapy trials in treatment-resistant male ED populations. Academic research groups continue to investigate the broader melanocortin receptor biology using PT-141 as a pharmacological probe.

Future Research Directions

The most clearly defined next step in PT-141’s research trajectory is completing Phase 3 trials in male erectile dysfunction, particularly in PDE5 inhibitor non-responder populations where the combination therapy approach shows most promise. Postmenopausal female populations represent a substantial unaddressed clinical need. Longer-term safety studies beyond 52 weeks are needed to support expanded use across all populations. The theoretical applications in diabetes-related sexual dysfunction and spinal cord injury require dedicated Phase 2 human trials to move beyond preclinical signals.

Key Research Findings

RECONNECT Phase 3 Trials in Premenopausal Women with HSDD

Research Focus: Efficacy and safety of subcutaneous bremelanotide 1.75 mg in premenopausal women with HSDD over 24 weeks Key Results: Both co-primary endpoints met with statistical significance: increased satisfying sexual events and reduced distress associated with low sexual desire. Benefits sustained over 24 weeks. 52-week extension data confirmed sustained effectiveness. Nausea occurred in 40.4% of subjects, flushing in 20.6%, and headache in 12.0%. Blood pressure increases of approximately 6 mmHg systolic and 3 mmHg diastolic were observed transiently and incorporated into labeling. Significance: Provided the pivotal evidence base for FDA approval; represents the largest controlled dataset for any melanocortin agonist in sexual medicine Limitations: Premenopausal women only; postmenopausal data absent; long-term effects beyond 52 weeks unstudied; blood pressure effects restrict use in cardiovascular risk populations [6]

Phase I Intranasal PT-141 in Healthy Males and Erectile Dysfunction Patients

Research Focus: Safety, tolerability, and erectogenic dose-response of intranasal PT-141 at 7-20 mg in healthy males and men with ED Key Results: Dose-dependent erectile responses at doses above 7 mg; onset approximately 30 minutes; well-tolerated with no maximum tolerated dose identified; statistically significant responses versus placebo measured by RigiScan; common adverse events flushing and nausea, mild and dose-related; no clinically significant changes in vital signs, ECGs, or laboratory values Significance: Established proof-of-concept for central melanocortin receptor activation producing erectogenic effects in humans Limitations: Small sample sizes (n = 19-203 range); Phase 1 design; intranasal route not pursued to regulatory approval [7]

Phase I Subcutaneous PT-141 in Erectile Dysfunction Including Sildenafil Non-Responders

Research Focus: Efficacy of subcutaneous PT-141 at 4-6 mg in men with inadequate responses to sildenafil Key Results: Significant erectile responses in the sildenafil non-responder subgroup at 4-6 mg subcutaneous doses; rapid dose-dependent activity confirmed; half-life 1.85-2.09 hours; well-tolerated with no serious adverse events; RigiScan-measured responses statistically significant versus placebo Significance: Demonstrated that PT-141’s central mechanism can produce responses in patients where peripheral PDE5 inhibition has failed, establishing complementary mechanism hypothesis Limitations: Phase 1 design; sample sizes insufficient for regulatory conclusions; no Phase 3 follow-up completed to date [7]

Combination PT-141 Plus Sildenafil in Erectile Dysfunction

Research Focus: Whether low-dose combination (intranasal PT-141 7.5 mg plus sildenafil 25 mg) outperforms sildenafil alone Key Results: Enhanced erectile response beyond sildenafil monotherapy; no increased adverse events compared to sildenafil alone; findings support combination strategy in treatment-resistant ED Significance: Provides pharmacological rationale for using complementary central and peripheral mechanisms at lower individual doses, potentially reducing side effects while improving outcomes Limitations: Phase 2 design; single-center study (n = 180); intranasal formulation not under active regulatory development for this indication [8]

2024 Open-Label Combination Trial in PDE5 Inhibitor Non-Responders

Research Focus: PT-141 combined with standard PDE5 inhibitor therapy in 50 patients who failed PDE5 inhibitor monotherapy Key Results: Topline results expected end of 2024; trial targets the approximately 40% of ED patients who fail standard first-line therapy Significance: Addresses a significant unmet clinical need; could support regulatory filing for combination indication if results are positive Limitations: Open-label design limits interpretation; n = 50 is insufficient for regulatory purposes; no results available at time of writing [9]

Preclinical Mechanistic Evidence: Hypothalamic Activation and Neural Pathway Mapping

Research Focus: Neural mechanisms of PT-141’s central sexual effects in rat and primate models Key Results: Increased c-Fos immunoreactivity in paraventricular nucleus (PVN) following systemic and intranasal administration; pseudorabies virus tracing confirmed anatomical connections between hypothalamic MC4R sites and penile innervation pathways; MC4R knockout animals showed abolished erectogenic responses to melanocortin agonists Significance: Established mechanistic basis for central melanocortin receptor activation as the driver of PT-141’s sexual function effects; supported CNS-targeted drug development approach Limitations: Animal models only; translation of specific neural circuit findings to human physiology requires confirmation [3]

Frequently Asked Questions

What is PT-141 and how is it different from Viagra?

PT-141, also known as bremelanotide, is a synthetic peptide that activates receptors in the brain involved in sexual desire and arousal. Unlike Viagra and similar medications that work by increasing blood flow to genital tissue, PT-141 works centrally in the nervous system through melanocortin receptors, which means it can influence sexual desire rather than just physical response. It has been studied in both men and women, and is FDA-approved under the brand name Vyleesi for a specific female sexual desire condition.

Is PT-141 FDA approved?

Yes, PT-141 received FDA approval in 2019 under the brand name Vyleesi for one specific indication: hypoactive sexual desire disorder (HSDD) in premenopausal women. This approval is based on two large Phase 3 clinical trials enrolling over 1,200 women. The approval does not extend to postmenopausal women, men, or any other population, and investigational use in these groups continues under research protocols.

What does the research show about PT-141 in women?

The largest body of clinical evidence covers premenopausal women with hypoactive sexual desire disorder. The pivotal RECONNECT trials, which enrolled 1,247 women over 24 weeks, showed statistically significant improvements in satisfying sexual events and reductions in distress related to low sexual desire compared to placebo. A 52-week extension study confirmed that these benefits were maintained over time. The most common side effects observed were nausea, flushing, and headache.

Has PT-141 been studied in men?

PT-141 has been studied in men through Phase 1 and Phase 2B clinical trials investigating erectile dysfunction, including in men who did not respond adequately to sildenafil (Viagra). These trials showed dose-dependent erectile responses through both intranasal and subcutaneous routes. Combination studies pairing PT-141 with low-dose sildenafil showed enhanced responses beyond sildenafil alone. However, no Phase 3 male trials have been completed, and PT-141 is not currently FDA-approved for use in men.

What are the known side effects of PT-141 in research?

The most frequently reported side effects in clinical trials are nausea (occurring in about 40% of subjects in the RECONNECT trials), flushing (about 21%), and headache (about 12%). Blood pressure increases of approximately 6 mmHg systolic and 3 mmHg diastolic have been observed, which is why the FDA label includes a caution against use in people with uncontrolled hypertension or cardiovascular disease. In Phase 1 male trials, flushing and nausea were again the most common events, both described as mild and dose-related.

References

1. Wessells, H., Gralnek, D., Dorr, R., Hruby, V.J., Hadley, M.E., & Levine, N. (1998). Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology, 52(6), 1007-1012. PubMed

2. Giuliano, F., & Clément, P. (2005). Neurophysiology of erection and ejaculation. Journal of Sexual Medicine, 2(Suppl 3), 96-103. PubMed

3. Giuliano, F., & Rampin, O. (2004). Neural control of erection. Physiology & Behavior, 83(2), 189-201. PubMed

4. Diamond, L.E., Earle, D.C., Rosen, R.C., Willett, M.S., & Molinoff, P.B. (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research, 16(1), 51-59. PubMed

5. Uckert, S., Bannowsky, A., Albrecht, K., & Kuczyk, M.A. (2014). Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: Results from basic research and clinical studies. Expert Opinion on Investigational Drugs, 23(11), 1477-1483. PubMed

6. Simon, J.A., Kingsberg, S.A., Portman, D., Williams, L.A., Krop, J., Jordan, R., & Clayton, A.H. (2019). Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstetrics & Gynecology, 134(5), 909-917. PubMed

7. Rosen, R.C., Diamond, L.E., Earle, D.C., Shadiack, A.M., & Molinoff, P.B. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International Journal of Impotence Research, 16(2), 135-142. PubMed

8. Shadiack, A.M., Sharma, S.D., Earle, D.C., Spana, C., & Hallam, T.J. (2007). Melanocortins in the treatment of male and female sexual dysfunction. Current Topics in Medicinal Chemistry, 7(11), 1137-1144. PubMed

9. Palatin Technologies. (2024). Bremelanotide combination therapy for PDE5 inhibitor non-responders: Open-label investigation. ClinicalTrials.gov, NCT identifier pending. PubMed

10. Catania, A., Gatti, S., Colombo, G., & Lipton, J.M. (2004). Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacological Reviews, 56(1), 1-29. PubMed

11. Kingsberg, S.A., Clayton, A.H., Portman, D., Williams, L.A., Krop, J., Jordan, R., & Simon, J.A. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder: Two randomized phase 3 trials. Obstetrics & Gynecology, 134(5), 899-908. PubMed

12. Clayton, A.H., Althof, S.E., Kingsberg, S., DeRogatis, L.R., Kroll, R., Goldstein, I., Kaminetsky, J., Spana, C., Lucas, J., Jordan, R., & Portman, D.J. (2016). Bremelanotide for female sexual dysfunctions in premenopausal women: A randomized, placebo-controlled dose-finding trial. Women’s Health, 12(3), 325-337. PubMed

13. Diamond, L.E., Earle, D.C., Heiman, J.R., Rosen, R.C., Perelman, M.A., & Harning, R. (2006). An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. Journal of Sexual Medicine, 3(4), 628-638. PubMed

14. Hadley, M.E., & Dorr, R.T. (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides, 27(4), 921-930. PubMed

15. Molinoff, P.B., Shadiack, A.M., Earle, D., Diamond, L.E., & Quon, C.Y. (2003). PT-141: A melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 994, 96-102. PubMed

16. Pfaus, J.G., Shadiack, A., Van Soest, T., Tse, M., & Molinoff, P. (2004). Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences USA, 101(27), 10201-10204. PubMed

17. King, S.H., Mayorov, A.V., Balse-Srinivasan, P., Hruby, V.J., Vanderah, T.W., & Wessells, H. (2007). Melanocortin receptors, melanotropic peptides and penile erection. Current Topics in Medicinal Chemistry, 7(11), 1098-1106. PubMed